Article Text

Download PDFPDF
Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries
  1. H P H Neumann1,
  2. M Salzmann1,
  3. B Bohnert-Iwan1,
  4. T Mannuelian2,
  5. C Skerka2,
  6. D Lenk2,
  7. B U Bender1,
  8. M Cybulla1,
  9. P Riegler3,
  10. A Königsrainer4,
  11. U Neyer5,
  12. A Bock6,
  13. U Widmer7,
  14. D A Male8,
  15. G Franke1,
  16. P F Zipfel2
  1. 1Department of Nephrology, Albert-Ludwigs-University, Freiburg, Germany
  2. 2Hans Knoell Institute for Natural Products Research, Department of Infection Biology, Jena, Germany
  3. 3Department of Nephrology, General Hospital, Bolzano, Italy
  4. 4Department of Surgery, University of Innsbruck, Austria
  5. 5Department of Nephrology, General Hospital, Feldkirch, Austria
  6. 6Department of Nephrology, General Hospital, Aarau, Switzerland
  7. 7Department of Internal Medicine Kantonsspital, Zürich, Switzerland
  8. 8Genetic Technologies Corp. Ltd, Melbourne, Australia
  1. Correspondence to:
 Professor Dr Hartmut P.H. Neumann Medizinische Universitätsklinik, Abteilung Nephrologie, Hugstetterstr. 55, D 79106 Freiburg i.B, Germany;


Background: The aetiology of atypical haemolytic uraemic syndrome (aHUS) is, in contrast to classical, Shiga-like toxin induced HUS in children, largely unknown. Deficiency of human complement factor H and familial occurrence led to identification of the factor H gene (FH1) as the susceptibility gene, but the frequency and relevance of FH1 mutations are unknown.

Methods: We established a German registry for aHUS and analysed in all patients and 100 controls the complete FH1 gene by single strand confirmational polymorphism and DNA sequencing. In addition, complement C3 and factor H serum levels were assayed. Demographic data at onset of aHUS and follow up were compared for the mutation positive and negative groups.

Results: Of 111 patients with aHUS (68 female, 43 male, mean age 33 years) 14% had FH1 germline mutations, including two of eight patients with familial aHUS.For each of these eight patients, both parents were tested, and we were able to trace the mutation for five cases. In the other three cases (one with the mutation 3749 C/T, one with 3200 T/C, and one with 3566+1 G/A), we could not detect the mutation in either parent, although paternity was proven by genetic fingerprinting, suggesting that these subjects have new mutations. C3 was decreased in five mutation carriers but also in two non-carriers, and factor H was decreased in none of the carriers, but elevated in six carriers and 15 non-carriers. Clinical parameters including associated medications and diseases, and outcome of aHUS and of post-aHUS kidney transplantation were similar in the mutation positive and negative groups.

Conclusion:FH1 germline mutations occur with considerable frequency in patients with aHUS. Hypocomplementaemia is not regularly associated with a germline mutation, and factor H serum levels can even be elevated. Screening for FH1 mutations contributes to the classification of aHUS.

  • aHUS, atypical haemolytic uraemic syndrome
  • HUS, haemolytic uraemic syndrome
  • Haemolytic uraemic syndrome
  • complement factor H
  • hypocomplementaemia
  • C3

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.